Effectiveness of baricitinib versus sarilumab on disease activity in patients with RA: a propensity score matching study
Compared with sarilumab, baricitinib improved swollen joints and the Clinical Disease Activity Index at 24 weeks; however, by 52 weeks, no significant difference was observed between the two groups, indicating that both treatments are important for long-term use.
Authors
- Tomonori Kobayakawa
- Yukio Nakamura
- Shin‐ichiro Ohmura (ORCID: https://orcid.org/0000-0001-8651-4149)
- Toshitaka Yukishima (ORCID: https://orcid.org/0000-0003-2265-6724)
Institutions
- Aichi Medical University (JP)
- Seirei Hamamatsu General Hospital (JP)
Publication Details
- Journal
- Rheumatology Advances in Practice
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1093/rap/rkaf006
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00